DIRECT ANTIVIRALS FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION. EXPERIENCE IN 106 PATIENTS

Nuevas terapias orales de acción directa para tratamiento de virus de hepatitis C (VHC).

Author
Vargas, Jose Ignacio; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.

Arab, Juan Pablo; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.

Monrroy, Hugo; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.

Labbe, Pilar; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.

Sarmiento, Valeska; Unidad de Hepatología Hospital Gustavo Fricke Viña del Mar

Fuster, Felipe; Unidad de Hepatología Hospital Gustavo Fricke Viña del Mar

Barrera, Francisco; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.

Benítez, Carlos; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.

Arrese, Marco; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.

Fuster, Francisco; Unidad de Hepatología Hospital Gustavo Fricke Viña del Mar

Soza, Alejandro; Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile.

Full text
http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/5693
Abstract
Background: The availability of direct-acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection is just starting to expand in Chile. Aim: To report the initial experience of patients treated with DAA and their evolution after treatment. Material and methods: Prospective cohort study, from June 2013 to August 2016 of patients treated with DAA for HCV in three clinical centers. The presence of cirrhosis, clinical and laboratory features; adverse events (AE) and post-treatment changes in liver function were evaluated. Sustained viral response at 12 weeks post-treatment (SVR12) was determined. Results: One hundred six patients aged 58 ± 13 years, 54% males, were included. HCV genotype 1b was present in 88% and 47% had cirrhosis. Treatment regimens were asunaprevir + daclatasvir (DCV) in 17% of patients, paritaprevir / ritonavir / ombitasvir + dasabuvir in 33%, sofosbuvir (SOF) + DCV in 19%, and SOF + ledipasvir in 30%. Twenty five percent of patients used generic drugs. SVR12 was 92.1%, with no differences between generic and brand-name drugs. Serious AE were recorded in 22% of patients, being more common in those with cirrhosis (34% vs 11.5%, p < 0.01). At 12 weeks post-treatment follow-up, there was a decrease in aminotransferase values (p
 
Background: The availability of direct-acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection is just starting to expand in Chile. Aim: To report the initial experience of patients treated with DAA and their evolution after treatment. Material and methods: Prospective cohort study, from June 2013 to August 2016 of patients treated with DAA for HCV in three clinical centers. The presence of cirrhosis, clinical and laboratory features; adverse events (AE) and post-treatment changes in liver function were evaluated. Sustained viral response at 12 weeks post-treatment (SVR12) was determined. Results: One hundred six patients aged 58 ± 13 years, 54% males, were included. HCV genotype 1b was present in 88% and 47% had cirrhosis. Treatment regimens were asunaprevir + daclatasvir (DCV) in 17% of patients, paritaprevir / ritonavir / ombitasvir + dasabuvir in 33%, sofosbuvir (SOF) + DCV in 19%, and SOF + ledipasvir in 30%. Twenty five percent of patients used generic drugs. SVR12 was 92.1%, with no differences between generic and brand-name drugs. Serious AE were recorded in 22% of patients, being more common in those with cirrhosis (34% vs 11.5%, p < 0.01). At 12 weeks post-treatment follow-up, there was a decrease in aminotransferase values (p
 
Metadata
Show full item record